简介：AIM:Toreviewpublishedclinicalstudiesexaminingtheeffectofnatamycininthetreatmentoffungalkeratitis.METHODS:WeselectedthepublicationsinCENTRAL,MEDLINE,EMBASE,CNKI,andCBM.Thisstudysystematicallyreviewedpublishedrandomizedcontrolledtrials(RCTs)thatcomparednatamycintootherantifungalagents,andconductedfeasibleMeta-analysisofefficacyresultsusingRevman5.2software.RESULTS:WeincludedseventrialswhichweremainlycarriedoutindevelopingcountriesofAsia,withfivetrialsconductedinIndia,oneeachinChinaandBangladesh.Atotalof804participantswererandomizedtofollowingcomparisons:2%econazoleversus5%natamycinshowedlittledifferenceintheeffectsoftreatmentoffungalkeratitis[RR=0.99,95%confidenceinterval(CI),0.8to1.21];chlorhexidinegluconateversus5%natamycinindicatedthattheresultsonhealingoftheulcerat21dwaslessconclusive(RR=0.77,95%CI,0.55to1.08;I2=0%);1%voriconazoleversus5%natamycinsuggestedthatnatamycintreatmentappearedtobesignificantlybetteroutcomesthanvoriconazole(regressioncoefficient=-0.18logMAR;95%CI,-0.30to-0.05;P=0.006),especiallyinFusariumcases(regressioncoefficient=-0.41logMAR;95%CI,-0.61to-0.20;P<0.001);natamycinversusfluconazoleshowedasignificantdifferenceincurerate(χ2=5.048,P<0.05)andnatamycingroupwasmoreeffectivethanfluconazoleinaverageperiodoftherapy(t=7.94,P<0.01).CONCLUSION:Natamycinwasapreferablechoiceinthetreatmentoffungalkeratitis,especiallyintheearlyperiodofFusariumcases.